Compare ADMA Biologics Inc (ADMA) vs KeyCorp (KEY) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ADMA Biologics Inc vs KeyCorp — how do they compare? ADMA Biologics Inc trades at $9.26 (market cap $2.13B), while KeyCorp trades at $22.68 (market cap $25.22B). The key difference: KeyCorp is far larger — about 11.8× ADMA Biologics Inc's market cap, and KeyCorp pays a 3.51% dividend while ADMA Biologics Inc pays none. Which is the better fit depends on your goals.
| ADMA | KEY | |
|---|---|---|
Market Cap | $2.13B | $25.22B |
Sector | Health | Financials |
52-Week High | $20.38 | $23.43 |
52-Week Low | $7.60 | $16.78 |
Enterprise Value | $2.20B | — |
Dividend Yield | — | 3.51% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADMA trades at $9.16, up 2.35% today, with a bullish technical signal from moving averages and oscillators. The company reported strong profitability with a 32.43% net income margin and 43.3% ROE for 2025, though recent EPS results were mixed. Analyst consensus is strongly bullish with an $19.00 price target, but multiple class action lawsuits filed in July 2026 alleging securities fraud create significant near-term uncertainty.
The stock offers substantial upside to analyst targets if legal challenges are resolved favorably, supported by robust fundamentals and projected cash flow growth. Primary risks include the outcome of ongoing litigation and potential reputational damage. Investors should weigh strong financial performance against elevated legal and sentiment risks before establishing a position.
KeyCorp (KEY) trades at $23.37, up 1.52% today, with a bullish technical signal and strong earnings momentum after three consecutive quarterly beats. The stock shows robust fundamentals with a P/E of 14.37, net income margin of 26.05%, and a new $3 billion buyback program. Recent news highlights its inclusion in dividend-focused strategies and potential for further earnings outperformance.
Outlook remains positive given analyst consensus of $29.55 price target and 60.79% buy ratings. Risks include volatile cash flows and banking sector sensitivity to interest rates, but capital returns and earnings growth support upside potential for investors seeking value and income.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ADMA Biologics Inc
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →About KeyCorp
With assets of over $170 billion, Ohio-based KeyCorp's bank footprint spans 16 states, but it is predominantly concentrated in its two largest markets: Ohio and New York. KeyCorp is primarily focused on serving middle-market commercial clients through a hybrid community/corporate bank model.
Read more on KEY →
